Vivos Therapeutics, Inc. (VVOS)
Healthcare
- Fundamental
- 1
- Sentiment
- 1
- Technical
- 1
Do Nothing: fundamentalScore 1 and qualitativeScore 1 both below the required floor of 3 (going-concern sub-$1 micro-cap), and liquidity fails the $5M floor (20-day avg ~$1.2M) and the $1.5M recent-liquidity floor (~$94K last 3 sessions).
Company overview
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Fundamental
very weakThe company's financial health is challenged by significant losses and cash burn.
Vivos Therapeutics, a sub-$0.30 micro-cap sleep-apnea company, disclosed an explicit going-concern warning in its August 2026 10-Q: about $1.8 million in cash cannot fund the next twelve months. Five straight years of losses, negative operating cash flow, negative book equity, and relentless dilution outweigh accelerating revenue and maintained analyst Buy ratings — too risky to invest.
Sentiment
very weakMedia and retail sentiment are mixed, with severe red flags including going-concern issues.
VVOS carries an active going-concern substantial-doubt disclosure (Q2-2026 10-Q filed 2026-08-14; ~$1.8M cash, negative book equity) that fires the severe red-flag cap, and the only actionable catalyst in the map is the Q2 print the market received as a miss — net loss, revenue below estimates, shares −6% (announced, trailing 12 days, partially priced). Sentiment delta is indeterminate (scoring-window polarity ≈ −0.14 at aggregator tier; no scored baseline polarity sample), and the severe red-flag cap is applied on going-concern/auditor doubt.
Technical
very weakThe stock shows a short-term bounce but remains in a broader downtrend with poor liquidity.
technicalScore 1 — bearish/broken structure: price below SMA20/50/200 and EMA9/21 with ADX14 27.75 trending lower; MACD below zero with the line under the signal; RSI 34.14 weak; Williams %R -95.27 pinned at the bottom of the 14-day range; no bullish confirmations across trend, momentum, or volume.
You’re looking at 2026-08-26 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.